about
Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent mannerInterfering with TGFbeta-induced Smad3 nuclear accumulation differentially affects TGFbeta-dependent gene expressionEndothelin receptors as novel targets in tumor therapyTargeting Bone Metastases in Metastatic Castration-Resistant Prostate CancerCytokines as Mediators of Pain-Related Process in Breast CancerImmune regulation of bone metastasisThe endothelin axis: emerging role in cancerMurine models of breast cancer bone metastasisPost-transcriptional regulation of cadherin-11 expression by GSK-3 and beta-catenin in prostate and breast cancer cells.Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.Mechanism of cancer pain.Pathogenesis of bone metastasis: a review.Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment.Treatment of malignant hypercalcaemia.Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell lineCadherin-11 in renal cell carcinoma bone metastasis.CD8+ T cells regulate bone tumor burden independent of osteoclast resorption.Zoledronic acid (Zometa) use in bone disease.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.Bone-immune cell crosstalk: bone diseases.Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signalingReceptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysisDisruption of CXCR4 enhances osteoclastogenesis and tumor growth in boneBisphosphonates and bone metastases: current status and future directions.Hypercalcemia in breast cancer: an echo of bone mobilization during lactation?Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivoThe endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications.A primer of bone metastases management in breast cancer patients.Interactions between microenvironment and cancer cells in two animal models of bone metastasisA tale of mice and (wo)men: development of and insights from an "all human" animal model of breast cancer metastasis to boneThe parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cellsCurcuminoids block TGF-β signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis.Pharmacotherapy of bone metastases in breast cancer patients.RANKL/RANK/OPG: key therapeutic target in bone oncology.Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?Breast cancer-derived factors stimulate osteoclastogenesis through the Ca2+/protein kinase C and transforming growth factor-beta/MAPK signaling pathways.Physiology and pathophysiology of the RANKL/RANK system.The immunomodulatory properties of mesenchymal stem cells.Contribution of bone tissue modulus to breast cancer metastasis to bone
P2860
Q24683680-01C374E7-3FA0-486E-A26B-7EAEC405680FQ24793548-E7BADB06-26A6-4EEC-83AD-01EF99FC2C83Q24797288-8BFF7450-DBC3-49F1-BECC-224837DC4C8FQ26752785-A69481DC-4AE4-4485-9E18-96DE3B91CEECQ26774863-C568D4A2-F567-4EFC-AD9B-4F967C60BBACQ27005871-7D531377-F247-4C05-8AD7-39C6F16B9D82Q28206793-CB0ED7EB-7B9A-49B9-80EE-C6D9A3AFD301Q30828525-7F49D559-F48A-49A9-93BE-FC201C3BB162Q33416408-F190AB18-C4E0-42C3-BBED-A042E07579C6Q33736180-8A8032C2-11EA-48FF-BB92-774DF74ED0A5Q33953901-F3F4180A-9DFD-4B37-B965-E6C335096847Q33993282-5AD15F2B-539F-48E8-A4AA-47E76DB7FD25Q34086847-49C52FB3-2767-41D1-88B5-32D5A825D97BQ34125314-E3E796A2-210E-4D0B-AEBD-AA5F50146572Q34628598-A20D2F60-3841-4CE5-AA9A-EE25D0C2DBA6Q35024363-17002254-CA89-416F-946D-1EB13E55343AQ35108264-94BD3EC5-177E-42DD-B2D3-D4C5D6A2F83AQ35112793-A105F936-6941-4D79-A798-2BDE28885788Q35117725-75460289-AC18-406A-A15C-22C60B69683DQ35550375-9180AAD0-0BE0-43BD-832E-AF6B97747E15Q35592362-BB824A9F-DCA4-4B7B-B0C0-DEE0B4E185B5Q35751362-3F15ABA6-D19E-482F-A44E-500C7A2635A3Q35843398-174D7330-C710-4926-BA24-40F8A42FF68FQ35956822-2CDD6B0F-0D49-4D4D-A95F-29E77ACBF296Q36118409-A761BA2D-B327-4D27-9293-4EB5D442D9E2Q36198198-67C17A5A-7785-4873-A66E-BA7DFDA00C50Q36245406-6987F1B4-78DB-4728-A9FC-B0BDCB9F6234Q36352082-08837064-702A-4C17-8183-5DD4A81BD214Q36410656-5B4962A1-2804-4FFA-A8C7-A8EB7EB3B7D0Q36484558-F52E79B2-E478-4D21-829E-C4B25D554D94Q36519704-64A17FB1-50CB-423B-8E7C-9268F516C248Q36649108-A6AC34CD-11FA-403E-9037-E2A48825515FQ36681248-EC4D6906-3F43-4864-BF33-BD7F2BC84DF5Q37123398-09ACFEC6-7E05-4150-B03E-6C7F39977291Q37140665-23EF4882-12A5-4DEF-AAE6-C0F555629C77Q37219226-FCD9774C-4832-49F0-9B42-FB651A4A8CE6Q37446271-25366087-C3B9-4D92-8E98-B731132E3212Q37810596-951C8F56-B54E-4B94-8E2C-B3989533B7F6Q37866167-11AFB179-7FA2-4C71-BDE0-11214D32E0DFQ37905720-924CBA6B-B295-4382-95C5-B60DF66CA32E
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Molecular mechanisms of osteolytic bone metastases.
@ast
Molecular mechanisms of osteolytic bone metastases.
@en
type
label
Molecular mechanisms of osteolytic bone metastases.
@ast
Molecular mechanisms of osteolytic bone metastases.
@en
prefLabel
Molecular mechanisms of osteolytic bone metastases.
@ast
Molecular mechanisms of osteolytic bone metastases.
@en
P2860
P1433
P1476
Molecular mechanisms of osteolytic bone metastases.
@en
P2093
P2860
P304
P356
10.1002/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO;2-Y
P407
P433
P577
2000-06-01T00:00:00Z